Shifting Medicine Forward

Drawing on a deep understanding of the underlying causes, Ichnos Sciences is pursuing truly disease-centric therapies in oncology and autoimmune conditions. We strive to develop novel assets and find new answers to some of medicine’s greatest challenges. Because the world is waiting.

Our path toward disease-centric therapies

Oncology Pipeline
Products Description Preclinical Phase 1 Phase 2 Phase 3 Status
ISB 1342
CD38 x CD3
BEAT® 1.0 bispecific antibody
Multiple Myeloma;
T-ALL under consideration*
      Phase 1
ISB 1442
CD38 x CD47 BEAT® 2.0 bispecific antibody
Multiple Myeloma;
Phase 1 Acute Myeloid
Leukemia (AML) planned
      PHASE 1
ISB 2001
BCMA x CD38 x CD3 TREAT™ trispecific antibody
Multiple Myeloma
      IND-Enabling Studies
Oncology Pipeline
Compound:
ISB 1342
Target:
CD38 x CD3
BEAT® 1.0 bispecific antibody
Indication:
Multiple Myeloma;
T-ALL under consideration*
Phase:
phase-1
Status:
Phase 1
Compound:
ISB 1442
Target:
CD38 x CD47 BEAT® 2.0 bispecific antibody
Indication:
Multiple Myeloma;
Phase 1 Acute Myeloid
Leukemia (AML) planned
Phase:
phase-1
Status:
PHASE 1
Compound:
ISB 2001
Target:
BCMA x CD38 x CD3 TREAT™ trispecific antibody
Indication:
Multiple Myeloma
Phase:
preclinical
Status:
IND-Enabling Studies


BEAT®Bispecific Engagement by Antibodies based on the T-cell receptor
TREAT™: Trispecific Engagement by Antibodies based on the T-cell receptor

 
Autoimmune Disease
Products Description Preclinical Phase 1 Phase 2 Phase 3 Status
ISB 830 (telazorlimab) (Licensing discussions ongoing)
OX40 antagonist monoclonal antibody
Atopic Dermatitis (AD)*
      Phase 2b completed
ISB 880 / ALM27134 (Licensed to Almirall S.A.)
IL-1RAP antagonist monoclonal antibody
Autoimmune Disease
      Phase 1
Autoimmune Disease
Compound:
ISB 830 (telazorlimab) (Licensing discussions ongoing)
Target:
OX40 antagonist monoclonal antibody
Indication:
Atopic Dermatitis (AD)*
Phase:
phase-2
Status:
Phase 2b completed
Compound:
ISB 880 / ALM27134 (Licensed to Almirall S.A.)
Target:
IL-1RAP antagonist monoclonal antibody
Indication:
Autoimmune Disease
Phase:
phase-1
Status:
Phase 1

*A US IND for rheumatoid arthritis and other autoimmune indications is active.

Primary efficacy endpoint (EASI score, % change, baseline to week 16) met at two highest doses tested. Numerical improvements were seen for the two higher-dose arms (300 mg and 600 mg q 2 weeks) of telazorlimab compared to placebo in the secondary endpoints of EASI-75 and Investigator Global Assessment, but the differences were generally not statistically significantly different from placebo.

Note: Assets that were previously identified as GBR XXXX are now identified as ISB XXXX.

View Career Opportunities

Career Opportunities

The link above is provided for your convenience, and Ichnos is not responsible for content, privacy, or security issues associated with your visit to external websites.